Pr Eric E. GabisonCornea and ocular surface · Paris
FR EN
HomeCorneal wound healing › Pathological healing
Course contents ▾
  1. Introduction & aims
  2. Epithelial healing
  3. Stromal healing
  4. Delayed healing & PED
  5. Corneal fibrosis (haze)
  6. Ulceration & CD147/MMP
  7. Angiogenic privilege
  8. Corneal neovascularization
  9. Summary & key points
  10. Summary table
  11. References
Chapter 2 of 4

Pathological healing

Delayed healing & persistent epithelial defect

Certain backgrounds weaken re-epithelialization: loss of corneal sensation (neurotrophic keratitis), diabetes, severe dry eye, limbal stem-cell insufficiency, chemical-burn sequelae or poor lid closure (exposure). A persistent epithelial defect (PED) fails to heal after about one week; unclosed, it thins the stroma and leads to a corneal ulcer [1,4].

Mechanisms of the main backgrounds

Neurotrophic keratitis reflects loss of the trophic support of corneal nerves (substance P, CGRP, IGF-1, NGF), essential to epithelial migration and adhesion. Diabetes combines hypoaesthesia, basement-membrane abnormalities and matrix glycation. Limbal insufficiency, congenital (aniridia) or acquired (burn), dries up epithelial renewal and lets the conjunctiva invade the cornea. Basement-membrane integrity is decisive: dystrophic abnormalities (e.g. Cogan / map-dot-fingerprint) sustain recurrent erosions.

Dry eye: barrier breakdown via the EMMPRIN–MMP-9–occludin axis

Dry eye epitomizes epithelial fragility. Tear hyperosmolarity activates the surface and, as we showed, raises EMMPRIN/CD147 and MMP-9, causing occludin cleavage and tight-junction disruption; genetic knockout of MMP-9 (or EMMPRIN) protects from this barrier breakdown (Huet et al., Am J Pathol 2011). This mechanism links surface inflammation directly to defective healing.

Iatrogenic factors

Several treatments slow healing: preservatives (benzalkonium, polyquaternium-1), topical NSAIDs, aminoglycosides, steroids and surface anaesthetics (proparacaine inhibits actin synthesis and hence migration). Finally, migration/proliferation desynchronization produces heaped-up edges that must be debrided.

Two bedside pitfalls

1) Raised (hyperplastic) epithelial edges block closure — debride them. 2) Fluorescein tracking under the edges suggests herpetic keratitis — the virus's cytopathic effect prevents edge cells from re-forming adhesions.

Corneal fibrosis (haze) & myofibroblasts

When the epithelium fails to close — or the basement membrane fails to regenerate — keratocytes remain continuously exposed to TGF-β1/β2 and PDGF, of epithelial origin. Once in the stroma, this initial signal triggers an autocrine loop: the differentiating myofibroblasts themselves begin producing TGF-β, while simultaneously inducing expression of its own receptor (TGF-βRI/II) — progressively freeing themselves from the initial epithelial signal to sustain their own differentiation. It is this loop that drives myofibroblasts to full maturity [3,5].

Present in large numbers near the wound, they deposit a disorganized matrix (fibronectin, collagen III, tenascin, glycosaminoglycans) and express, besides α-SMA, vimentin and desmin. These cells and their matrix scatter light: this is corneal fibrosis, clinically haze. One schematically distinguishes early haze (cellular, often regressive) from late haze (matrix, more stubborn).

The process is not always permanent. If the epithelial basement membrane reforms early enough, stromal TGF-β and PDGF fall, the autocrine loop loses its support and shuts down, myofibroblasts undergo apoptosis, and keratocytes recolonize and reorganize the matrix — the opacity may regress or clear over several years. After severe injuries, the autocrine loop may instead have become self-sustaining enough for the opacity to remain permanent despite re-epithelialization [6].

Haze is best studied after surface ablation (PRK): the intensity of the wound-healing response (keratocyte apoptosis then myofibroblast density) explains the differences in haze and regression between PRK and LASIK, and underlies the use of intra-operative mitomycin C for large corrections [13,14].

Haze: reversible or permanent

The fate of the opacity hinges on basement-membrane reformation: while absent, the inflow of epithelium-derived TGF-β and PDGF feeds the autocrine loop that sustains myofibroblasts; once it reforms, the epithelial supply dries up — but if the autocrine loop has already become self-sustaining (receptor induced, TGF-β self-production), the door stays shut and the opacity may persist regardless. This rationale underlies strategies that preserve or restore the EBM as early as possible [3].

→ See also: upstream of this epithelial TGF-β, corneal macrophages are the main source of the TGF-β and PDGF that sustain this loop — TGF-β's role in detail in the dedicated sub-chapter.

Ulceration, stromal melting & direct epithelial–stromal interactions (CD147/MMP)

Without closure, stromal thinning can progress to perforation, faster on an inflammatory background or with iatrogenic agents. After the initial injury, the underlying keratocytes first undergo apoptosis; in normal healing they then recolonize the anterior stroma as the epithelial basement membrane reforms, which keeps them separated from the epithelium. Prolonged delay, however, prevents this basement-membrane maturation — sometimes down to disappearance of Bowman's layer, which, unlike the epithelial basement membrane, does not regenerate once destroyed: that same recolonization then brings the epithelium into direct, potentially lasting contact with the subepithelial keratocytes — the direct epithelial–stromal interactions (DESI), which are always pathological [4,5].

EMMPRIN/CD147: metalloproteinase inducer

This pathological dialogue is largely mediated by the transmembrane glycoprotein EMMPRIN/CD147 (Extracellular Matrix Metalloproteinase Inducer, basigin). In direct contact with fibroblasts, the epithelium expresses CD147, which induces stromal MMP synthesis (MMP-1, -2, -3, -9) and promotes myofibroblast differentiation. Weakly present in the healthy cornea (mostly epithelial), it is strongly overexpressed in ulcerated corneas, induced in the anterior stroma and co-localized with MMP-2 at the epithelial–stromal boundary; in vitro, direct contact of fibroblasts with EMMPRIN-rich epithelial membranes induces MMP-1/-2, an effect abolished by a blocking anti-EMMPRIN antibody — evidence of CD147's causal role (Gabison et al., Am J Pathol 2005). This deregulated induction sustains collagenolysis and delayed healing, making CD147 a therapeutic target (Gabison et al., Prog Retin Eye Res 2009). The same EMMPRIN → MMP-9 axis also destabilizes the epithelial barrier by cleaving occludin (Huet et al., 2011).

Melting or fibrosis? The inversion of TGF-β's role

In diffusible signalling, TGF-β predominates over IL-1, inhibits collagenase expression and drives matrix accumulation: differentiation is directed toward a fibrotic myofibroblast (haze). At the site of direct epithelial-stromal contact, however, EMMPRIN expression remains under the transcriptional control of TGF-β, whose function is then reversed: anti-proteolytic under diffusible signalling, it becomes pro-lytic by inducing the CD147 → MMP axis. The result is a distinct phenotype, the lytic myofibroblast — an MMP producer rather than a matrix producer, likewise α-SMA⁺ but with the opposite outcome, preferentially found in ulcerated corneas where matrix degradation predominates (Gabison et al., 2009). A single marker can thus correspond to two functionally opposite phenotypes: it is the induction pathway — diffusible TGF-β signalling versus direct EMMPRIN-mediated contact — that determines whether myofibroblast differentiation follows a fibrotic or a lytic course.

MMP / TIMP balance and vicious circle

MMPs are zinc-dependent endopeptidases that degrade matrix and basement membrane; their activity is normally reined in by tissue inhibitors (TIMP) and serum inhibitors (α2-macroglobulin) — hence the value of autologous serum. In inflammation, excessive infiltration of monocytes, macrophages and neutrophils releases surplus MMP: the balance shifts to collagenolysis and the stroma thins. Rheumatoid arthritis, often TIMP-deficient, is the classic example (central melts). A vicious circle sets in: collagen-degradation products are chemotactic for neutrophils, summoning a fresh inflammatory wave and more MMP [5,4].

CD147/EMMPRIN: a hub and a target

An MMP inducer at the epithelial–stromal interface and a barrier regulator (occludin), CD147 links stromal melting, delayed healing and dry-eye barrier breakdown. Its overexpression signals the breakdown of the synthesis/degradation balance that normally protects the stroma — hence its appeal as a therapeutic target. MMP inhibitors (chelators, tetracyclines — anti-collagenolytic independently of antibacterial action) round out the arsenal.

→ For a detailed review of anti-MMP/anti-melt agents and the full range of pharmacological modulators of corneal healing (evidence levels, regulatory availability, full bibliography), see Factors modulating corneal wound healing — past, present and future (36 detailed agent fact sheets, with sourced bibliography).

→ On the specific role of macrophages in this MMP/TIMP balance, see the sub-chapter Corneal macrophages — NLRP3, MIF, TGF-β & fibrosis.

→ For a full course dedicated to the EMMPRIN/CD147 mechanism and direct epithelial–stromal interactions (anatomical barriers, amplification loop, two healing outcomes), see Pathological corneal healing: direct epithelial–stromal interactions.

Glossary of abbreviations used in this course

Scientific abbreviations and acronyms used throughout the 10 pages of this course, listed alphabetically.

95% CI
95% confidence interval
AAV
adeno-associated virus (gene-therapy viral vector)
ABCG2
ABCG2 transporter, a limbal stem-cell marker
AMT
amniotic membrane transplantation
anti-VEGF
anti-angiogenic treatment targeting VEGF
ASC
inflammasome adaptor protein (Apoptosis-associated Speck-like protein containing a CARD)
BrdU
bromodeoxyuridine, a cell-proliferation marker
CCL2
CCL2 chemokine, synonym of MCP-1; recruits circulating monocytes
CCR2
receptor for CCL2; marker of newly recruited monocytes/macrophages
CD147
cluster of differentiation 147; synonym of EMMPRIN and basigin
CD163
M2 macrophage marker; scavenger receptor for haemoglobin-haptoglobin
CD206
mannose receptor; marker of M2 polarization
CD74
cell-surface receptor for MIF
CDVA
corrected distance visual acuity
CGRP
calcitonin gene-related peptide
CTGF
connective tissue growth factor
CX3CL1
fractalkine, a chemokine involved in monocyte/macrophage recruitment
CXCR2/CXCR4
chemokine receptors, also receptors for MIF
DAMP
damage-associated molecular pattern
DESI
direct epithelial–stromal interaction
EGF
epidermal growth factor
EGFR
epidermal growth factor receptor
EMMPRIN
extracellular matrix metalloproteinase inducer; synonym of CD147
ETDRS
reference visual-acuity scale used in clinical research (Early Treatment Diabetic Retinopathy Study)
FasL
Fas ligand, an apoptosis-inducing protein
FISH
fluorescence in situ hybridisation
GAG
glycosaminoglycan(s)
GM-CSF
granulocyte-macrophage colony-stimulating factor
GVHD
graft-versus-host disease
HGF
hepatocyte growth factor
HIF-3α
hypoxia-inducible factor, 3-alpha subunit
HMGB1
high mobility group box 1, an alarmin released by injured cells (DAMP)
IFN-γ
interferon gamma
IGF-1
insulin-like growth factor 1
IL-1
interleukin-1
iNOS
inducible nitric oxide synthase
IPAS
inhibitory PAS domain protein
KGF
keratinocyte growth factor
LASIK
laser-assisted in situ keratomileusis
LogMAR
logarithmic visual-acuity scale
LOX
lysyl oxidase, a collagen cross-linking enzyme
LPS
bacterial lipopolysaccharide
M1
classically activated macrophage, pro-inflammatory profile
M2
alternatively activated macrophage, pro-resolving/reparative profile (subtypes M2a-M2d, M2eff)
MEN2B
multiple endocrine neoplasia type 2B
MerTK
receptor tyrosine kinase involved in efferocytosis
MIF
macrophage migration inhibitory factor
MRI
magnetic resonance imaging
NGF
nerve growth factor
NK
neurotrophic keratitis
NLRP3
NLRP3 inflammasome (NOD-, LRP- and pyrin domain-containing protein 3)
NO
nitric oxide
NSAID
nonsteroidal anti-inflammatory drug
PACAP
pituitary adenylate cyclase-activating polypeptide
PAF
platelet-activating factor
PAMP
pathogen-associated molecular pattern
PDGF
platelet-derived growth factor
PED
persistent epithelial defect
PEDF
pigment epithelium-derived factor
PGE₂
prostaglandin E2
PRK
photorefractive keratectomy (laser surface ablation)
pro-NGF
precursor form of NGF
RGTA
matrix-therapy ReGeneraTing Agent, e.g. Cacicol
rhNGF
recombinant human NGF (cenegermin)
ROS
reactive oxygen species
Smad
signalling proteins of the TGF-β pathway
SPK
superficial punctate keratitis
sVEGFR-1
soluble form of VEGF receptor-1 (= sFlt-1)
sVEGFR-3
soluble form of VEGF receptor-3
TGF-β
transforming growth factor beta
TIMP
tissue inhibitor of metalloproteinases
TLR
Toll-like receptor
TNF-α
tumour necrosis factor alpha
TRPV4
transient receptor potential vanilloid 4, a mechanosensitive ion channel
uPA
urokinase-type plasminogen activator
V1
ophthalmic branch of the trigeminal nerve
VEGF
vascular endothelial growth factor
VEGF-C
lymphangiogenic isoform of VEGF
VIP
vasoactive intestinal peptide
YAP/TAZ
Hippo pathway effectors, mechanosensors of matrix stiffness
α-SMA
alpha-smooth muscle actin, a myofibroblast marker